Intellia Therapeutics, Inc.

NTLA - CIK 0001652130

Market cap$1.73 B

Rank#2213

SEC filings687

Intellia Therapeutics, Inc. trades as NTLA and has a market capitalization of $1.73 B, making it the #2213 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $67.67M, up 16.9% from the prior year and net income of -$412.69M. This page tracks Intellia Therapeutics, Inc. through 687 SEC filings, with financial statements and metrics updated as new reports are filed.

Key metrics

Revenue (latest FY)$67.67MFY 2025

Net income (latest FY)-$412.69MFY 2025

Operating cash flow (latest FY)-$394.74MFY 2025

Total assets (latest FY)$842.13MFY 2025

Net margin-609.9%latest FY

Financial performance

Over the last 9 fiscal years Intellia Therapeutics, Inc.'s revenue grew from $16.48M to $67.67M, a compound annual growth rate of 17.0%. Net profit margin compressed from -192.0% to -609.9% over the same period - every figure below comes from the company's audited annual filings.

NTLA annual revenueView details

Key statistics

Market cap: $1.73 B
Share price (derived)market cap / shares outstanding: $12.36
EPS (diluted)FY 2025: $-3.81
Shares outstandingas of 2026-04-30: 0.14B
Total equityas of 2026-03-31: $620.94M
Return on equity: -66.5%
Cash & equivalentsas of 2026-03-31: $134.70M
Current ratioas of 2026-03-31: 6.10

Latest filings

Filing	Type	Filed
Quarterly report	10-Q	2026-05-11
Major company event	8-K	2026-05-11
SCHEDULE 13G	-	2026-04-30
Major company event	8-K	2026-04-30
Annual report to shareholders	ARS	2026-04-30
Proxy materials	DEFA14A	2026-04-30
Proxy statement	DEF 14A	2026-04-30
SCHEDULE 13G	-	2026-04-29

Browse the full filing history (687 filings)

Recent press releases

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 20262026-06-01
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026 - Intellia Therapeutics
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates2026-05-11
Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates - Intellia Therapeutics
Intellia Therapeutics to Participate in Upcoming Investor Conferences2026-05-05
Intellia Therapeutics to Participate in Upcoming Investor Conferences - Intellia Therapeutics
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)2026-05-01
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Intellia Therapeutics
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock2026-04-29
Intellia Therapeutics Announces Pricing of Public Offering of Common Stock - Intellia Therapeutics

Similar companies

The largest companies sharing Intellia Therapeutics, Inc.'s SEC industry classification (in vitro & in vivo diagnostic substances).

IDXXIDEXX Laboratories, Inc.$43.93 B NTLA vs IDXX

LNTHLantheus Holdings, Inc.$6.63 B NTLA vs LNTH

CLDXCelldex Therapeutics, Inc.$2.30 B NTLA vs CLDX

NEOGNeogen Corporation$2.01 B NTLA vs NEOG

NNNNAnbio Biotechnology$1.50 B NTLA vs NNNN

Frequently asked questions

What is Intellia Therapeutics, Inc.'s market cap?

Intellia Therapeutics, Inc. (NTLA) has a market capitalization of $1.73 B as of 2026-06-10, ranking #2213 among US-listed companies.

How much revenue does Intellia Therapeutics, Inc. make?

Intellia Therapeutics, Inc. reported revenue of $67.67M for fiscal year 2025, an increase of 16.9% year over year.

Is Intellia Therapeutics, Inc. profitable?

In its latest fiscal year Intellia Therapeutics, Inc. reported a net loss of $412.69M.

Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.